Mounjaro Weight Loss Treatment in Bangalore | TODS

Advanced GLP-1 Therapy

Mounjaro Weight Loss Treatment in Bangalore

Mounjaro (Tirzepatide) is revolutionizing obesity medicine with clinical results that rival bariatric surgery. Discover how TODS provides safe, medically supervised Mounjaro therapy with personalized assessment and ongoing care.

📅 Schedule Your Consultation 💬 WhatsApp: +91 9845 374 457

Understanding Mounjaro

The Next Generation of Weight Loss Medication

Mounjaro (Tirzepatide) has rapidly become one of the most talked-about advances in obesity medicine — and for good reason. As a dual-action GLP-1 and GIP receptor agonist, it represents a significant step forward from earlier weight loss medications, with clinical trials demonstrating weight loss outcomes that rival some bariatric surgical procedures.

In Bangalore, where rising obesity rates and metabolic disease burden are a growing public health concern, Mounjaro offers a scientifically grounded non-surgical option for eligible patients. But accessing it safely — through proper medical evaluation, appropriate prescribing, and structured follow-up — is what separates genuine treatment from risky self-experimentation.

At TODS, we provide Mounjaro therapy as part of a fully supervised medical weight loss programme. This approach ensures that every patient receives the benefit of this powerful medication while maintaining the safety protocols that evidence-based medicine demands.

💊

Quick Navigation

01 What Is Mounjaro (Tirzepatide)? 02 How Mounjaro Differs From Other Medications 03 Clinical Evidence: What the Trials Show 04 Who Is Eligible for Mounjaro? 05 The TODS Mounjaro Treatment Protocol 06 Dosing Schedule and Titration 07 Common Side Effects & Management 08 Mounjaro Cost in Bangalore 09 FAQs 10 Medical Review 11 Serving Bangalore 12 Get Started

The Medication

What Is Mounjaro (Tirzepatide)?

Mounjaro is the brand name for Tirzepatide, a weekly injectable medication developed by Eli Lilly. It is a dual agonist of two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

Originally approved for type 2 diabetes management, Tirzepatide has demonstrated such significant weight loss in clinical trials that it is now recognised globally as a major advance in obesity pharmacotherapy. Eli Lilly launched the Mounjaro KwikPen in India in August 2025.

The Advantage

How Mounjaro Differs From Other Medications

Most GLP-1 medications — including Semaglutide (Ozempic/Wegovy) — target the GLP-1 receptor only. Mounjaro's dual action on both GLP-1 and GIP receptors appears to produce synergistic metabolic effects. In direct comparisons, Tirzepatide has consistently outperformed Semaglutide in average weight loss outcomes.

This does not mean Mounjaro is the right choice for every patient. Individual response varies based on metabolic profile, starting weight, comorbidities, tolerance, and other factors. A physician-led assessment is the only way to determine the most appropriate medication for a given patient.

Dual Receptor Action: GLP-1 + GIP combined effect

Greater Appetite Suppression: More potent appetite reduction

Superior Weight Loss: 20.9% average vs 14.9% for pure GLP-1

Enhanced Metabolic Control: Better blood sugar & lipid management

Proven Results

Clinical Evidence: What the Trials Show

20.9%

SURMOUNT-1 Trial

Average body weight reduction at highest dose (15 mg) over 72 weeks — matching bariatric surgery outcomes

15%

Mid-Dose Results

Approximately 15% weight loss achieved at 10 mg weekly dose — still significantly superior to other medications

98%

Maintenance Rate

SURMOUNT-4 demonstrated that continued use maintains weight loss; discontinuation leads to gradual regain

Medical Assessment

Who Is Eligible for Mounjaro?

✅

General Eligibility Guidelines

Mounjaro is generally appropriate for adults with a BMI of 27.5 or above (South Asian threshold) with at least one weight-related comorbidity, or BMI of 32.5 or above regardless of comorbidity.

✓ Type 2 diabetes (excellent candidate)

✓ Hypertension requiring management

✓ Dyslipidaemia or metabolic syndrome

✓ Sleep apnoea or respiratory issues

⚕️

Comprehensive Assessment

Eligibility is always determined through clinical evaluation — these are starting criteria, not automatic qualifications. Every TODS patient receives full metabolic, cardiovascular, and safety screening.

⚠️

Contraindications

Mounjaro is not appropriate for patients with:

× Personal/family history of medullary thyroid carcinoma

× MEN2 syndrome (Multiple Endocrine Neoplasia type 2)

× Active pancreatitis or severe GI disorders

× Pregnancy/breastfeeding or planning pregnancy

× Severe renal/hepatic impairment

Structured Care

The TODS Mounjaro Treatment Protocol

Initial Assessment

Full blood work, body composition, cardiovascular screening, and detailed medical history review.

Personalised Plan

Medication selection, starting dose, and individualised titration schedule based on your profile.

Monthly Monitoring

Weight tracking, blood pressure, glucose monitoring, side-effect review, and nutritional guidance.

Long-Term Support

Ongoing physician guidance, dose adjustments, and exit planning for sustainable results.

Treatment Schedule

Dosing Schedule and Titration

Mounjaro is administered as a once-weekly subcutaneous injection. The standard titration schedule begins at 2.5 mg weekly for four weeks, then increases at regular intervals as tolerated.

A slower titration than the standard schedule is sometimes appropriate for patients who experience significant gastrointestinal side effects. Our physicians individualise the titration rate accordingly.

Week 1–4: 2.5 mg weekly

Week 5–8: 5 mg weekly

Week 9–12: 7.5 mg weekly

Week 13+: 10 mg, 12.5 mg, or 15 mg

Safety & Management

Common Side Effects & How to Manage Them

Most Common Side Effects

Gastrointestinal side effects like nausea, constipation, or diarrhoea are most pronounced during dose increases and typically resolve within 1–2 weeks.

🤢 Nausea — Usually mild, resolves quickly

🔄 Constipation/Diarrhoea — Transient, manageable

Management Strategies

Eat smaller, frequent meals. Stay hydrated. Avoid high-fat foods around injection day. Physician guidance ensures optimal comfort throughout treatment.

Rare Serious Effects

Acute pancreatitis, gallbladder disease, hypoglycaemia. Screened for during follow-ups. Contact physician if you experience severe abdominal pain or symptoms of low blood sugar.

TODS Safety Protocol

Regular monitoring, detailed pre-treatment counselling, clear guidance on when to seek immediate care, and physician-supervised dose adjustments ensure your safety throughout treatment.

Pricing Information

Mounjaro Cost in Bangalore (2026)

As of mid-2026, Mounjaro (Eli Lilly KwikPen) starts at approximately ₹3,281 per weekly injection in India — which equates to roughly ₹13,125 per month at the 2.5 mg starter dose.

Cost increases with higher doses as you progress through your titration schedule. These are medication costs only and do not include consultation fees, investigations, or programme management charges.

At TODS, we are transparent about total programme costs during the initial consultation and help patients plan accordingly.

2.5 mg dose ~₹13,125/month

5–7.5 mg dose ~₹16,400/month

10 mg dose ~₹20,625/month

12.5–15 mg dose ~₹25,781/month

Common Questions

Frequently Asked Questions

Q: Is Mounjaro available in Bangalore?

Yes. Mounjaro (Tirzepatide) is available in India and can be prescribed by qualified physicians in Bangalore. At TODS, we offer it as part of a fully supervised weight loss programme.

Q: Can I buy Mounjaro without a prescription?

Mounjaro is a prescription medication. You should not use it without a doctor's evaluation. Obtaining it without proper assessment is unsafe and not recommended.

Q: How quickly does Mounjaro work?

Most patients notice appetite suppression within the first 1–2 weeks. Meaningful weight loss typically becomes apparent by 8–12 weeks, with peak effects seen over 12–24 months.

Q: Is Mounjaro better than Ozempic?

Clinical trials show Mounjaro produces greater average weight loss than Semaglutide. However, the best medication is the one clinically appropriate for your individual profile. A thorough evaluation determines this.

Q: Can I use Mounjaro if I have type 2 diabetes?

Yes, Mounjaro is particularly well-studied in people with type 2 diabetes. Dose adjustments to other diabetes medications may be required. This is managed carefully at TODS.

Q: Is the TODS clinic accessible from Whitefield?

Yes. Our clinic is reachable from East Bangalore including Whitefield and Marathahalli via Outer Ring Road. We offer scheduled appointments to minimise travel disruption.

⚕️

Medical Review Notice

Clinical Accuracy Certified

This article has been reviewed for clinical accuracy by the medical team at Dr. Tulip's Obesity & Diabetes Surgery Centre (TODS). Information reflects evidence-based clinical practice and does not constitute personalised medical advice. Please consult a qualified physician before starting Mounjaro therapy.

Reviewed by: Dr. Tulip, MS, FMAS, FIAGES

Senior Bariatric & Metabolic Surgeon | Specialist in Obesity Medicine, Bariatric Surgery, Metabolic Health | TODS India, Bangalore

Serving Bangalore

TODS: Locally Accessible, Medically Rigorous

💉

Interested in Mounjaro for Weight Loss?

Start with a comprehensive medical assessment at TODS. Our physicians will evaluate your health, discuss your goals, and determine if Mounjaro is the right choice for you.

📅 Book Your Consultation 💬 WhatsApp: +91 9845 374 457